ADME Study of [14C]-PF05212384 in healthy male volunteers (QBR116743)

• Research type

  Research Study

• Full title

  A Phase One, Open-Label single-radiolabelled dose study to investigate the metabolism, and excretion of [14C] PF-05212384 in helathy male volunteers

• IRAS ID

  154999

• Contact name

  Mari Evans

• Contact email

  N/A

• Sponsor organisation

  Pfizer Inc.

• Eudract number

  2014-001366-96

• Clinicaltrials.gov Identifier

  NCT02142920

• Research summary

  Pfizer, the sponsor, are developing the study drug (PF-05212384) for the treatment of advanced solid tumours in adult patients.

  This study has been designed to look at how the study drug is taken up, broken down and removed by the body.

  The study will involve approximately 6 healthy male subjects. Subjects will receive a single 30 minute IV infusion 89 mg dose of PF-05212384 containing radiolabelled [14C]-PF-05212384.

• REC name

  Wales REC 1

• REC reference

  14/WA/0180

• Date of REC Opinion

  19 Jun 2014

• REC opinion

  Further Information Favourable Opinion